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Introduction
While obesity is an established risk factor for a first venous thromboembolism (VTE) [1] [2] [3] [4] , whether obesity is also associated with recurrent VTE is controversial. Several studies found that a higher body mass index (BMI) is independently associated with recurrent VTE [5] [6] [7] but others did not [8] [9] [10] .
More than 60% of VTE episodes occur in patients aged 65 years or older [11] . As elderly patients were underrepresented in prior studies demonstrating a relationship between an increased BMI and recurrent VTE (mean patient age 49-62 years) [5] [6] [7] , whether obesity is a risk factor for recurrent VTE in the elderly is unknown. Moreover, as the muscle mass decreases in older age and is replaced by fat ("sarcopenic obesity"), the BMI may not increase with obesity in the elderly, and the waist circumference (WC), a measure of abdominal fat distribution, may be more important than the BMI to examine health risks associated with obesity in the elderly [12] . We evaluated the association between two measures of body weight, the BMI and the WC, and recurrent VTE in a prospective cohort of elderly patients with acute VTE. We also examined the quality of anticoagulation across BMI categories.
Patients and methods
The study was conducted between September 2009 and December 2013 as part of the SWIss venous Thromboembolism COhort (SWITCO65+), a prospective multicenter cohort study that assessed long-term medical outcomes in elderly patients with acute VTE from all five university and four high-volume non-university hospitals in Switzerland. Consecutive patients aged !65 years with an acute, objectively confirmed symptomatic VTE were identified in the in-and outpatient services of all participating study sites. A detailed description of the study methods was published elsewhere [13] . The Institutional Review Board at each participating center approved the study and patients gave written consent to participation. The approving ethics committee was the "Kantonale Ethikkommission Bern."
Trained study nurses prospectively collected baseline demographics (age, sex), comorbid conditions (diabetes mellitus, arterial hypertension, immobilization, chronic pulmonary disease, cerebrovascular disease, active cancer, chronic liver and renal disease, heart failure, inflammatory bowel disease, presence of hemiparesis, hemiplegia, or paraplegia, prior varicose vein surgery [as a proxy for varicose veins]), type of the index VTE (unprovoked, provoked, or cancer-related), prior history of VTE, localization of VTE (PE ±DVT vs. DVT alone), family history of DVT or PE, estrogen therapy, concomitant antiplatelet therapy, and VTE-related treatments (low-molecular-weight heparin, unfractionated heparin, fondaparinux, and vitamin K antagonists) using standardized data collection forms. At study entry the BMI was calculated (weight in kilograms divided by height in meters squared) and categorized as normal (<25 kg/m [14, 15] .
The outcome was the time to a first recurrent VTE during follow-up, defined as new or recurrent, symptomatic, and objectively confirmed pulmonary embolism (PE), including fatal PE, or proximal and/or distal deep vein thrombosis (DVT) based on previously published criteria [13] . We defined distal DVT as any DVT below the popliteal vein. Follow-up started after enrolment and included one telephone interview and two surveillance face-to-face evaluations during the first year of study participation, then semi-annual contacts alternating between face-to-face evaluations (clinic visits or home visits in house-bound patients) and telephone calls, as well as periodic reviews of the patient's hospital chart. During each visit/contact, study nurses interviewed patients to obtain information about recurrent VTE and assessed whether or not the patient had died. We also collected international normalized ratio (INR) values throughout the period of follow-up. If a clinical event had occurred, supplemental information was obtained by reviewing medical charts and interviewing the patient's primary care physician and/or family members. All outcomes were reviewed and adjudicated by a committee of three blinded clinical experts. Based on the full consensus of this committee, deaths were classified as definitely due to PE (e.g., confirmed by autopsy or following severe PE), possibly due to PE (e.g., sudden death without obvious cause), or due to other causes.
We compared the percentage of time spent within one of three specified INR ranges (<2.0, 2.0-3.0, >3.0) across BMI categories according to the Rosendaal method using the nonparametric Kruskal-Wallis rank test [16] . We calculated the incidence rates of VTE by BMI and WC category and also compared the cumulative incidence of a first recurrent VTE using Kaplan-Meier curves and the log-rank test. We examined the association between obesity measures and the time to a first VTE recurrence using competing risk regression, accounting for non-VTE related death as a competing event [17] . We adjusted for risk factors that have been previously shown to be associated with recurrent VTE, including age, sex, heart failure, inflammatory bowel disease, presence of hemiparesis, hemiplegia, or paraplegia, prior varicose vein surgery (as a proxy for varicose veins), type of the index VTE (unprovoked, provoked, or cancer-related), prior history of VTE, localization of VTE (PE ±DVT vs. DVT alone), family history of DVT or PE, and periods of anticoagulation as a time-varying covariate [6, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . We repeated the same analyses using percentile-based BMI/WC categories (>10 th , 10-90 th , and >90 th percentile). We further stratified analyses by sex and age group (65-75 vs. >75 years) and performed several sensitivity analyses by excluding patients with prior VTE, cancer, BMI <18.5 kg/m 2 and isolated distal DVT. We also excluded the period of initial anticoagulation in another sensitivity analysis. All analyses were done using Stata 14 (Stata Corp., College Station, Texas).
Results
Of the 1863 screened patients aged !65 years with acute VTE, 462 had at least one exclusion criterion and 398 did not consent to participate. Of the 1003 participating patients, 58 withdrew their consent and four were lost to follow-up. These patients were considered in the analysis, i.e. they were censored at the time of withdrawal or loss to follow-up. We excluded 17 patients (8 denied use of data, 4 withdrew from study within one day, and 5 with no BMI reported), our final study sample comprising 986 elderly patients with acute VTE. (14) 51 (15) 53 (13) 31 (13) Cerebrovascular disease** 91 (9) 33 (10) 34 (8) 24 (10) Heart failure † † 115 (12) 41 (12) 37 (9) 37 (15) Inflammatory bowel disease 32 (3) 15 (4) 11 (3) 6 (2) Hemiparesia, hemiplegia, or paraplegia 28 (3) 10 (3) 8 (2) 10 (4) Prior varicose vein surgery 136 (14) 38 (11) 64 (16) 34 (14) Type of VTE Abbreviations: BMI = body mass index; VTE = venous thromboembolism; PE = pulmonary embolism; DVT = deep vein thrombosis; AC = anticoagulation; LMWH = Low-molecular-weight-heparin; VKA = vitamin K antagonist. ‡ Immobilization (bed rest >72 hours, fracture or cast of the lower extremity, voyage in sitting position >6 hours) during the last 3 months before index VTE. ¶ Chronic obstructive pulmonary disease, active asthma, lung fibrosis, cystic fibrosis, or bronchiectasis. **History of ischemic or hemorrhagic stroke or hemiparesis, hemiplegia, or paraplegia at the time of screening. † † Known history of systolic or diastolic heart failure, left or right heart failure, forward or backward heart failure, left ventricular ejection fraction of <40%, or acute heart failure (NYHA III/IV) during the last 3 months. *Any VTE unrelated to cancer or major surgery, immobilization, or estrogen therapy during the last 3 months before index VTE. † Solid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, and/or palliative care during the last 3 month before index VTE. § Estrogen therapy during the last 3 months before index VTE. (Fig 1) . Similarly, the 3-year cumulative incidence of recurrent VTE did not vary by WC and was 21% for patients with a WC <80 cm (w) / <94 cm (m), 14% for patients with a WC 80 to <88 cm (w) / 94 to <102 cm (m), and 14% for patients with a WC !88 cm (w) / !102 cm (m) (P = 0.49) (Fig 2) . Overall, patients spent 65% of their time in the therapeutic INR range (2.0-3.0). The time spent in therapeutic INR range was 62%, 67%, and 64% for patients with a BMI <25 kg/m (Table 3 ). There was no association between BMI as a continuous variable and recurrent VTE (SHR 1.02, 95% CI 0.98-1.05). Similarly, we found no association between WC as categorical or continuous variable and recurrent VTE (Table 3) . Stratified analyses yielded similar results for men vs. women (S1 Table) and for patients aged 65 to 75 years vs. >75 years (S2 Table) . When using percentile-based cut-offs for obesity measures, we did not find a higher incidence rate and risk of recurrent VTE in patients in the 90 th BMI and WC percentile (S3 Table) . Similarly, when . The 3-year cumulative incidence of a first recurrent venous thromboembolism was 17.6%, 11.5%, and 17.0% for patients with a body mass index <25, 25 to <30, and >30 kg/m 2 , respectively (P = 0.09 by the logrank test).
https://doi.org/10.1371/journal.pone.0184868.g001
Obesity and recurrent VTE we excluded patients with cancer (S4 Table) , isolated distal DVT (S5 Table) , BMI <18.5 kg/m 2 (S6 Table) , and prior VTE (S7 Table) in sensitivity analyses, there was no association between excess body weight and VTE recurrence. When we considered only follow up periods after the completion of the initial anticoagulation period in a sensitivity analysis, the results did not change (data not shown).
Discussion
In this prospective multicenter cohort of elderly patients with acute VTE, neither the BMI nor the WC was associated with recurrent VTE. Overall, anticoagulation quality did not substantially vary across BMI categories. In contrast to prior cohort studies enrolling mostly younger patients with VTE (mean age 49-62 years) [5] [6] [7] [8] [9] [10] , the median age was 75 years in our cohort.
While we found no association between measures of body weight and VTE recurrence, several factors could attenuate a potential relationship between obesity and recurrent VTE in the elderly. As the body weight physiologically decreases after the age of 70 years [31] , obese patients were younger and potentially healthier than non-obese patients in our study, as shown by the lower prevalence of cancer in obese patients. Moreover, unknown confounders such as systemic diseases could be responsible for weight loss and cause a higher risk of recurrent VTE in non-obese patients. Thus, we cannot exclude the possibility that despite adjustment for known risk factors such as cancer, patients with a higher body weight may have been healthier and at lower risk of recurrent VTE. Overall, our results indicate that an increased body weight does not confer a higher risk of recurrent VTE in elderly patients and that weight loss is unlikely to result in a reduced thrombosis risk in obese older patients with VTE. The results remained unchanged in various subgroup and sensitivity analyses, which further strengthens our conclusion that obesity is not associated with recurrent VTE in elderly patients. Our study has potential limitations. First, BMI and WC were only measured at study entry and potential weight changes during follow up could not be considered. Finally, because only 2.4% of patients had a BMI <18.5 kg/m 2 , we could not explore whether underweight, possibly due to comorbid conditions, was associated with recurrent VTE. However, the results did not change when patients with a BMI <18.5 kg/m 2 were excluded, confirming the robustness of our findings.
In conclusion, measures of body weight were not associated with recurrent VTE in our prospective cohort of elderly patient. Obesity does not appear to be a predictor of recurrent VTE in the elderly and weight loss is unlikely to result in a reduced thrombosis risk in obese older patients with VTE. 
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